Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears

An executive at Maze Therapeutics exercised and sold 30,000 shares on March 10, 2026, generating approximately $1.51M in gross proceeds at a weighted-average price of ~$50.45 per share. This is a routine insider sale likely driven by liquidity needs or compensation exercise and is unlikely to have meaningful impact on the stock or company fundamentals.

Analysis

An executive at Maze Therapeutics exercised and sold 30,000 shares on March 10, 2026, generating approximately $1.51M in gross proceeds at a weighted-average price of ~$50.45 per share. This is a routine insider sale likely driven by liquidity needs or compensation exercise and is unlikely to have meaningful impact on the stock or company fundamentals.